These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38301697)

  • 1. The GLOW trial in chronic lymphocytic leukaemia.
    van Gelder M; Hoogendoorn M; Te Raa D
    Lancet Oncol; 2024 Feb; 25(2):e55. PubMed ID: 38301697
    [No Abstract]   [Full Text] [Related]  

  • 2. The GLOW trial in chronic lymphocytic leukaemia.
    Fey M
    Lancet Oncol; 2024 Feb; 25(2):e54. PubMed ID: 38301696
    [No Abstract]   [Full Text] [Related]  

  • 3. The GLOW trial in chronic lymphocytic leukaemia - Authors' reply.
    Niemann CU; Kater AP
    Lancet Oncol; 2024 Feb; 25(2):e56. PubMed ID: 38301698
    [No Abstract]   [Full Text] [Related]  

  • 4. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia.
    Rider TG; Grace RJ; Newman JA
    Br J Haematol; 2016 Apr; 173(2):326-7. PubMed ID: 26195269
    [No Abstract]   [Full Text] [Related]  

  • 5. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
    Manda S; Dunbar N; Marx-Wood CR; Danilov AV
    Br J Haematol; 2015 Sep; 170(5):734-6. PubMed ID: 25716177
    [No Abstract]   [Full Text] [Related]  

  • 6. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia--response to Rider et al.
    Danilov AV
    Br J Haematol; 2016 Apr; 173(2):327-8. PubMed ID: 26195155
    [No Abstract]   [Full Text] [Related]  

  • 7. NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
    Mikudina B; Goodall M; Adler AI
    Lancet Oncol; 2017 Mar; 18(3):289-290. PubMed ID: 28130034
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
    van der Straten L; Levin MD; Visser O; Blijlevens NMA; Cornelissen JJ; Doorduijn JK; Kater AP; Dinmohamed AG
    Br J Haematol; 2020 Mar; 188(6):e109-e112. PubMed ID: 31991479
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic lymphocytic leukaemia therapy: is less more?
    Walter HS; Dyer MJS
    Lancet Haematol; 2022 Mar; 9(3):e169-e171. PubMed ID: 35240069
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
    Mato AR; Timlin C; Ujjani C; Skarbnik A; Howlett C; Banerjee R; Nabhan C; Schuster SJ
    Br J Haematol; 2018 Apr; 181(2):259-261. PubMed ID: 28220935
    [No Abstract]   [Full Text] [Related]  

  • 12. A new era of treatment for chronic lymphocytic leukaemia?
    Brown JR
    Lancet Oncol; 2014 Jan; 15(1):3-5. PubMed ID: 24332240
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID: 31402323
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.